BioSpace News Archive

Surgalign Holdings, Inc. today announced that the Company’s HOLO Portal surgical guidance system has officially entered clinical use.

Daewoong Pharmaceutical announced its financial results for the first quarter of 2022.

In 2020, 3.7% of U.S. adults currently used electronic nicotine delivery systems 1 with 18.5% of users reporting gingival pain and or oral bleeding2 making this a concerning human health threat.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA targeted 177Lu-PNT2002 program remains on schedule and has not experienced any issues or delays related to clinical drug supply.

Arcturus Therapeutics Holdings Inc. provided updated data from its Phase 1/2 booster clinical trial showing durability of antibody response with ARCT-154 for at least three months after low-dose booster.

Novotech, the leading Asia-Pacific biotech specialist CRO, has acquired US CRO NCGS as part of its expansion program, and can now offer its biotech clients clinical services in the US to support later phase global studies.

Oryzon Genomics, S.A. reported financial results for the first quarter of 2022 and provided an update on recent developments.

Subsequent to study results previously released by Spinal Resources Inc, the U.S. Patent and Trademark Office has issued the Variable-Dimension/Variable-Stiffness Spinal Fixation Rod with Bezier Surface Geometry a patent.

RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a commercial update on Thursday, May 12, 2022, before U.S. financial markets open.

DAB.bio, pioneers in biomanufacturing fermentation technology, announced successful fermentation runs in their FAST bioreactor, demonstrating that the technology lowers the unit cost of fermentation-based production at scale.